CN117567572A - 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 - Google Patents
一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 Download PDFInfo
- Publication number
- CN117567572A CN117567572A CN202311587402.1A CN202311587402A CN117567572A CN 117567572 A CN117567572 A CN 117567572A CN 202311587402 A CN202311587402 A CN 202311587402A CN 117567572 A CN117567572 A CN 117567572A
- Authority
- CN
- China
- Prior art keywords
- rbd
- delta
- vaccine
- omicron
- chimeric antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 74
- 102000036639 antigens Human genes 0.000 title claims abstract description 50
- 108091007433 antigens Proteins 0.000 title claims abstract description 50
- 239000000427 antigen Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 37
- 229960005486 vaccine Drugs 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 25
- 230000003612 virological effect Effects 0.000 claims description 20
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 16
- 230000002163 immunogen Effects 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 10
- 108020004705 Codon Proteins 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 239000007922 nasal spray Substances 0.000 claims description 4
- 229940097496 nasal spray Drugs 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 claims description 3
- 108010041986 DNA Vaccines Proteins 0.000 claims description 2
- 229940021995 DNA vaccine Drugs 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 108700021021 mRNA Vaccine Proteins 0.000 claims description 2
- 229940126582 mRNA vaccine Drugs 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 229940126583 recombinant protein vaccine Drugs 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000006190 sub-lingual tablet Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 229940023147 viral vector vaccine Drugs 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 6
- 230000001681 protective effect Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 2
- 229940027499 ZF2001 vaccine Drugs 0.000 description 88
- 102000004169 proteins and genes Human genes 0.000 description 66
- 108090000623 proteins and genes Proteins 0.000 description 66
- 235000018102 proteins Nutrition 0.000 description 51
- 241000699670 Mus sp. Species 0.000 description 36
- 210000004072 lung Anatomy 0.000 description 30
- 230000003472 neutralizing effect Effects 0.000 description 26
- 238000010828 elution Methods 0.000 description 25
- 241001112090 Pseudovirus Species 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 23
- 108020005004 Guide RNA Proteins 0.000 description 21
- 239000000539 dimer Substances 0.000 description 19
- 241000700605 Viruses Species 0.000 description 18
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 16
- 108091027544 Subgenomic mRNA Proteins 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 230000027455 binding Effects 0.000 description 14
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 14
- 239000002808 molecular sieve Substances 0.000 description 13
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229910052759 nickel Inorganic materials 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102100031673 Corneodesmosin Human genes 0.000 description 7
- 101710139375 Corneodesmosin Proteins 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 229940023143 protein vaccine Drugs 0.000 description 6
- 235000014304 histidine Nutrition 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 241001678559 COVID-19 virus Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000012505 Superdex™ Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108700023317 Coronavirus Receptors Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 150000002411 histidines Chemical class 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 210000004879 pulmonary tissue Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241000008904 Betacoronavirus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 101000773743 Homo sapiens Angiotensin-converting enzyme Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311587402.1A CN117567572A (zh) | 2022-04-01 | 2022-04-01 | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311587402.1A CN117567572A (zh) | 2022-04-01 | 2022-04-01 | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 |
| CN202210340144.6A CN114634556B (zh) | 2022-04-01 | 2022-04-01 | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210340144.6A Division CN114634556B (zh) | 2022-04-01 | 2022-04-01 | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117567572A true CN117567572A (zh) | 2024-02-20 |
Family
ID=81950939
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311587402.1A Pending CN117567572A (zh) | 2022-04-01 | 2022-04-01 | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 |
| CN202210340144.6A Active CN114634556B (zh) | 2022-04-01 | 2022-04-01 | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210340144.6A Active CN114634556B (zh) | 2022-04-01 | 2022-04-01 | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN117567572A (fr) |
| WO (1) | WO2023186170A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023079529A1 (fr) * | 2021-11-05 | 2023-05-11 | King Abdullah University Of Science And Technology | Compositions d'immunisation de rappel de protéine de refocalisation et leurs méthodes d'utilisation |
| CN117567572A (zh) * | 2022-04-01 | 2024-02-20 | 中国科学院微生物研究所 | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 |
| CN115124626A (zh) * | 2022-05-11 | 2022-09-30 | 中国科学院微生物研究所 | 串联式杂合三聚体新冠疫苗 |
| CN114773465B (zh) * | 2022-06-20 | 2022-08-26 | 北京市疾病预防控制中心 | 一种针对新冠病毒omicron株S蛋白的单域抗体VHH-3及编码序列和应用 |
| CN117327174A (zh) * | 2022-06-24 | 2024-01-02 | 广东菲鹏制药股份有限公司 | 抗新型冠状病毒人源化多价结合蛋白及其应用 |
| CN115197331A (zh) * | 2022-06-28 | 2022-10-18 | 中国科学院微生物研究所 | 新冠病毒三聚体嵌合疫苗及其用途 |
| CN115716866A (zh) * | 2022-09-30 | 2023-02-28 | 珠海丽凡达生物技术有限公司 | 新型冠状病毒疫苗及其制备方法和应用 |
| CN117582492A (zh) * | 2022-08-12 | 2024-02-23 | 上海市公共卫生临床中心 | 重组多价疫苗 |
| CN117070535B (zh) * | 2023-10-17 | 2024-01-26 | 中国医学科学院医学生物学研究所 | 具有体液免疫和细胞免疫功能的新冠病毒突变体广谱疫苗 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220054521A1 (en) * | 2020-03-31 | 2022-02-24 | Phoenix Biotechnology, Inc. | Method and Compositions for Treating Coronavirus Infection |
| CN113230395B (zh) * | 2020-05-29 | 2022-07-19 | 中国科学院微生物研究所 | 一种β冠状病毒抗原、β冠状病毒二联疫苗及其制备方法和应用 |
| CN113292640B (zh) * | 2021-06-18 | 2021-12-24 | 国药中生生物技术研究院有限公司 | 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用 |
| CN113999321B (zh) * | 2021-12-24 | 2022-09-13 | 中国科学院微生物研究所 | 一种具有广谱中和活性的新冠病毒抗体及其制备方法与应用 |
| CN114044821B (zh) * | 2022-01-10 | 2022-03-25 | 中国人民解放军军事科学院军事医学研究院 | 一种抗新冠病毒全人源广谱中和抗体zwc12及应用 |
| CN114181962B (zh) * | 2022-01-17 | 2022-06-07 | 北京翊博普惠生物科技发展有限公司 | 一种新型冠状病毒mRNA疫苗及其制备方法与应用 |
| CN114150005B (zh) * | 2022-02-09 | 2022-04-22 | 广州恩宝生物医药科技有限公司 | 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗 |
| CN117567572A (zh) * | 2022-04-01 | 2024-02-20 | 中国科学院微生物研究所 | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 |
-
2022
- 2022-04-01 CN CN202311587402.1A patent/CN117567572A/zh active Pending
- 2022-04-01 CN CN202210340144.6A patent/CN114634556B/zh active Active
-
2023
- 2023-04-03 WO PCT/CN2023/085915 patent/WO2023186170A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114634556B (zh) | 2023-12-19 |
| WO2023186170A1 (fr) | 2023-10-05 |
| CN114634556A (zh) | 2022-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114634556B (zh) | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 | |
| WO2022184027A1 (fr) | Nouvel antigène multivalent de coronavirus, son procédé de préparation et son utilisation | |
| CN113230395B (zh) | 一种β冠状病毒抗原、β冠状病毒二联疫苗及其制备方法和应用 | |
| CN106928326B (zh) | 一种基于二聚化的受体结合区亚单位的冠状病毒疫苗 | |
| CN113943373B (zh) | 一种β冠状病毒多聚体抗原、其制备方法和应用 | |
| CN113912710B (zh) | 抗新型冠状病毒n蛋白的单克隆抗体及其应用 | |
| CN111606993B (zh) | 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用 | |
| CN114106164B (zh) | 抗新型冠状病毒s蛋白的单克隆抗体及其应用 | |
| CN107488217A (zh) | 一种多肽、免疫原性偶联物和流感疫苗 | |
| CN115925822A (zh) | 一种重组蛋白及其在制备呼吸道合胞病毒疫苗中的应用 | |
| CN115724999B (zh) | 串联式杂合三聚体新冠疫苗 | |
| CN113461810A (zh) | 一种抗新型冠状病毒刺突蛋白的全人源单克隆抗体及其应用 | |
| CN116082521A (zh) | 痘病毒多抗原嵌合疫苗及其用途 | |
| CN111073861A (zh) | 人呼吸道合胞病毒毒株、应用、抗体或杂交瘤细胞或抗血清 | |
| JP5097135B2 (ja) | Ｂ型肝炎ワクチンの免疫応答を促進するタンパク質およびその遺伝子 | |
| CN110204613B (zh) | 一种针对胡宁病毒的中和抗体、其制备方法及其应用 | |
| CN113150082A (zh) | 呈递sars-cov-2的rbm不同区域肽表位的病毒样颗粒疫苗构建方法 | |
| JP6902804B2 (ja) | Ｂ型肝炎ウイルス様粒子をアジュバントとして含むワクチン組成物 | |
| CN106337038B (zh) | 一种通过转肽酶剪切制备疫苗的方法及其应用 | |
| CN118005783B (zh) | 一种抗呼吸道合胞病毒抗体及其应用 | |
| CN115975042B (zh) | 一种β冠状病毒异源多聚体抗原、其制备方法和应用 | |
| CN114716541B (zh) | 抗冠状病毒的全人广谱中和抗体76e1及其应用 | |
| CN115043915B (zh) | 一种增强新冠病毒变异株免疫原性的方法及其应用 | |
| JP7391997B2 (ja) | 豚熱ウイルス感染を予防するための組換えタンパク質、それを含む組成物及び細胞 | |
| CN117050193A (zh) | 一种β冠状病毒重组嵌合抗原、其制备方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |